Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing
Total Tic Severity in children and adolescents with Tourette's Disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.